Patents Assigned to Ionis Phamaceuticals, Inc.
  • Modulation of transthyretin expression
    Patent number: 9816092
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: November 14, 2017
    Assignee: Ionis Phamaceuticals, Inc.
    Inventors: Brett P. Monia, Susan M. Freier, Andrew M. Siwkowski, Shuling Guo